|
|
|
|
|
Denileukin diftitox
drug data and news
Denileukin diftitox drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Denileukin diftitox | ||
| Brand Names/Synonyms | Diphtheria toxin precursor;DT;NAD(+--diphthamide ADP- ribosyltransferase); Ontak (Seragen Inc) | ||
| Indication | For treatment of cutaneous T-cell lymphoma | ||
| Sponsored links | Description | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1 -Thr 387 )-His followed by the sequences for interleukin-2 (IL-2; Ala 1 -Thr 133 ). It is produced in an E. coli expression system. | |
| Pharmacology | Denileukin diftitox (Ontak) directs the cytocidal action of diphtheria toxin to cells which express the IL-2 receptor. The human IL-2 receptor exists in three forms, low (CD25), intermediate (CD122/CD132) and high (CD25/CD122/CD132) affinity. Malignant cells expressing one or more of the subunits of the IL-2 receptor are found in certain leukemias and lymphomas including cutaneous T-cell lymphoma (CTCL). Ontak interacts with the high affinity IL-2 receptor on the cell surface and inhibits cellular protein synthesis, resulting in cell death within hours. | ||
| Mechanism Of Action | Ontak binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells. | ||
| Denileukin diftitox News (When available) |
Business Wire (press release), Ligand Pharmaceuticals Incorporated (Pink Sheets:LGND) cancer drug ONTAK(R) (denileukin diftitox) benefits patients with relapsed/refractory T-cell and B-cell ... Phase II Study Demonstrates that ONTAK Benefits Patients with ... Dec 15, 2005 PharmaLive.com (press release), SAN DIEGO--(BUSINESS WIRE)--Dec 14, 2005--Ligand Pharmaceuticals Incorporated (Pink Sheets:LGND) cancer drug ONTAK(R) (denileukin diftitox) benefits patients ... | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Antineoplastic Agents | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Diptheria toxin-Interleukin-2 fusion protein | ||
| Chemical Formula | C2560H4042N678O799S17 | ||
| Molecular Weight | 57647.3 | ||
| Smiles String | Not Available | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.301 | ||
| Isoelectric Point | 5.45 | ||
| Biotransformation | Not Available | ||
| Half Life | 70-80 min | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Denileukin_diftitox.html http://www.rxlist.com/cgi/generic2/denileukin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00084 | ||
| CAS Registry Number | 64365-503-01 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA10317 | ||
| SwissProt ID | DTX_COROM (P00587) | ||
| GenBank ID | V01536 | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |